Original Research Article

Molecular Profiles of Pyramidal Neurons in the Superior Temporal Cortex in Schizophrenia

Charmaine Y. Pietersen¹,², Sarah A. Mauney¹, Susie S. Kim¹, Maribel P. Lim¹, Robert J. Rooney³, Jill M. Goldstein⁴, Tracey L. Petryshen⁴, Larry J. Seidman⁴, Martha E. Shenton⁴, Robert W. McCarley²,⁶,⁷, Kai-C. Sonntag²,⁸ and Tsung-Ung W. Woo¹,²,⁶

¹Laboratory of Cellular Neuropathology, McLean Hospital, Belmont, Massachusetts, USA
²Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
³Genome Explorations Inc., Memphis, Tennessee, USA
⁴Department of Psychiatry, Brigham and Women’s Hospital, Boston, Massachusetts, USA
⁵Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA
⁶Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
⁷Department of Psychiatry, Veterans Affairs Boston Healthcare System, Brockton, Massachusetts, USA
⁸Department of Psychiatry, McLean Hospital, Belmont, Massachusetts, USA

Abstract: Disrupted synchronized oscillatory firing of pyramidal neuronal networks in the cerebral cortex in the gamma frequency band (i.e., 30–100 Hz) mediates many of the cognitive deficits and symptoms of schizophrenia. In fact, the density of dendritic spines and the average somal area of pyramidal neurons in layer 3 of the cerebral cortex, which mediate both long-range (associational) and local (intrinsic) corticocortical connections, are decreased in subjects with this illness. To explore the molecular pathophysiology of pyramidal neuronal dysfunction, we extracted ribonucleic acid (RNA) from laser-captured pyramidal neurons from layer 3 of Brodmann’s area 42 of the superior temporal gyrus (STG) from postmortem brains from schizophrenia and normal control subjects. We then profiled the messenger RNA (mRNA) expression of these neurons, using microarray technology. We identified 1331 mRNAs that were differentially expressed in schizophrenia, including genes that belong to the transforming growth factor beta (TGF-β) and the bone morphogenetic proteins (BMPs) signaling pathways. Disturbances of these signaling mechanisms may in part contribute to the altered expression of other genes found to be differentially expressed in this study, such as those that regulate extracellular matrix (ECM), apoptosis, and cytoskeletal and synaptic plasticity. In addition, we identified 10 microRNAs (miRNAs) that were differentially expressed in schizophrenia; enrichment analysis of their predicted gene targets revealed signaling pathways and gene networks that were found by microarray to be dysregulated, raising an interesting possibility that dysfunction of pyramidal neurons in schizophrenia may in part be mediated by a concerted dysregulation of gene network functions as a result of the altered expression of a relatively small number of miRNAs. Taken together, findings of this study provide a neurobiological framework within which specific hypotheses about the molecular mechanisms of pyramidal cell dysfunction in schizophrenia can be formulated.

Keywords: cerebral cortex, gene expression profiling, laser-capture microdissection, microRNA, schizophrenia

INTRODUCTION

Gray matter volume in the cerebral cortex has been consistently found to be decreased in patients with schizophrenia (Ananth et al., 2002; Wilke et al., 2001). The superior temporal gyrus (STG) is one of the cortical regions that exhibit the most pronounced volumetric reduction (McCarley et al., 1999; Yamasue et al., 2004). This reduction is thought to reflect a decrease in the number of synapses (Selemon & Goldman-Rakic, 1999), the majority of which appear to be located on the dendritic spines of pyramidal neurons (Glantz & Lewis, 2000; Sweet et al., 2009).

Pyramidal neurons in the cerebral cortex exhibit layer-specific connectional properties, providing neural circuit architectures that support distinct aspects of higher cortical functions. For instance, dendritic spines on pyramidal neurons in layer 3 are targeted by both local and long-range glutamatergic projections in a highly reciprocal fashion. Synchronized activities of pyramidal
neuronal networks through these connections, especially in the gamma frequency band (i.e., 30–100 Hz), are critical for the integrity of higher cortical functions (Buzsaki & Draguhn, 2004). Disturbances of these networks may contribute to the pathophysiology of schizophrenia by compromising gamma oscillation (Arnsten et al., 2010; Lewis & Gonzalez-Burgos, 2008; Uhlhaas & Singer, 2010). This concept is supported by the following postmortem and clinical observations. First, the density of dendritic spines on pyramidal neurons in layer 3 of the cerebral cortex, including the STG, have been shown to be decreased by 23–66% in subjects with schizophrenia (Costa et al., 2001; Garey et al., 1998; Glantz & Lewis, 2000; Sweet et al., 2009). Second, consistent with these findings, the average somal area of these pyramidal cells is significantly smaller (Sweet et al., 2003, 2004). Third, in the prefrontal cortex, the density of glutamatergic axonal boutons, of which dendritic spines are their major targets, was significantly decreased by as much as 79% in layer 3 (but not in layer 5) in subjects with schizophrenia (Bitanihirwe et al., 2009). Finally, an increasing number of clinical studies have consistently demonstrated that gamma oscillatory synchrony is impaired in patients with schizophrenia (Cho et al., 2006; Kwon et al., 1999; Spencer et al., 2004; Uhlhaas & Singer, 2010). Furthermore, gamma impairment has been linked to the symptoms and cognitive deficits of the illness, and their severity has in turn been associated with the magnitude of cortical gray matter reduction (Cascella et al., 2010; Gur et al., 1999, 2000; Mitelman et al., 2003; Suga et al., 2010). Taken together, understanding the molecular underpinnings of pyramidal cell functional impairment will shed important light onto the pathophysiology and thereby the conceptualization of novel and rational treatment of cortical dysfunction in schizophrenia.

In order to identify the molecular correlates of pyramidal cell dysfunction in schizophrenia, we combined laser-capture microdissection (LCM) with Affymetrix microarray and high-throughput TaqMan-based MegaPlex quantitative reverse transcriptase–polymerase chain reaction (qRT-PCR), respectively, to elucidate the alterations in messenger RNA (mRNA) and microRNA (miRNA) expression profiles of these neurons in layer 3 of the STG. We found that transforming growth factor beta (TGF-β) and bone morphogenetic protein (BMP) signaling pathways and many genes that regulate extracellular matrix (ECM), apoptosis and cytoskeleton were dysregulated in schizophrenia. In addition, we identified 10 differentially expressed miRNAs; the predicted targets of which included the dysregulated pathways and gene networks identified by microarray analysis. Together these findings provide a conceptual framework within which we can begin to formulate and test specific hypotheses of the neurobiological mechanisms that underlie pyramidal cell dysfunction in schizophrenia.

MATERIALS AND METHODS

Postmortem Human Brain Tissue

Liquid nitrogen vapor fresh-frozen blocks, approximately 3 mm thick and containing the STG (Brodmann’s area 42), matched for age, sex, pH, and postmortem interval (PMI) (Table 1), were obtained from the Harvard Brain Tissue Resource Center (HBTRC) at McLean Hospital, Belmont, Massachusetts. Postmortem human brain collection procedures of the HBTRC, including the informed consent process, have been approved by the Partners Human Research Committee. Written informed consent for use of each of the brains for research has been obtained by the legal next of kin. All of the brains included in this study were examined by a Board-certified neuropathologist to rule out any neurological disorders. In addition, the fact that none of the subjects had any active history of substance abuse or dependence was confirmed by toxicological analysis. A detailed methodology for tissue preparation, LCM and RNA processing has been described in detail elsewhere (Pietersen et al., 2009, 2011).

LCM

Sections of 8 μm were cut on a cryostat, mounted on slides and stored at – 80°C until use. Pyramidal neurons were stained with the Histogene quick staining kit (Applied Biosystems, Foster City, CA) and identified based on the pyramidal morphology and the clearly identifiable proximal apical and basal dendrites (Figure 1). In addition, pyramidal neurons that were in close proximity to any nonpyramidal cells were excluded in order to avoid cellular contamination. Pyramidal neurons were removed using the Arcturus XT system (Applied Biosystems). Approximately 500 neurons per subject were captured onto a CapSure HS LCM cap (Applied Biosystems) for the microarray experiment whereas approximately 100 cells were captured for miRNA profiling. To avoid systematic biases, samples from schizophrenia and normal control subjects were processed for LCM in a random order.

Affymetrix Platform–Based Microarray Gene Expression Profiling

RNA Processing

RNA isolation was performed using the Picopure RNA isolation kit (Life Technologies, Grand Island, NY), with a DNase step (Qiagen, Valencia, CA). This typically resulted in approximately 1–25 ng of total RNA (Table 2) (Pietersen et al., 2009, 2011). Total RNA integrity was evaluated by RNA Quality Indicator (RQI) generated
Table 1. Subjects included in this study.

| Group          | Sexa | Age  | PMI  | pH   | Smoker | Cause of death             | Antipsychoticd |
|----------------|------|------|------|------|--------|----------------------------|-----------------|
| Control        | F    | 79   | 15.00| 6.59 | Yes    | Cardiac arrest             | N/A             |
| Control        | M    | 22   | 21.47| 6.75 | Yes    | Myocardial infarction      | N/A             |
| Control        | M    | 75   | 20.25| 6.35 | Yes    | Unknown                    | N/A             |
| Control        | M    | 80   | 15.50| 6.26 | Yes    | Myocardial infarction      | N/A             |
| Control        | F    | 58   | 21.08| 6.79 | No     | Myocardial infarction      | N/A             |
| Control        | M    | 61   | 17.00| 6.64 | Yes    | Unknown                    | N/A             |
| Control        | F    | 71   | 20.50| 6.89 | Unknown| Unknown                    | N/A             |
| Control        | F    | 90   | 12.66| 6.10 | Unknown| Lung cancer                | N/A             |
| Control        | F    | 86   | 6.92 | 5.74 | Unknown| Myocardial infarction      | N/A             |
| Mean ± SEM     | 4M/5F| 69.11±6.85 | 16.71±1.60 | 6.46±0.12 |  |
| Schizophrenia  | F    | 93   | 6.92 | 6.13 | Unknown| Renal failure              | Perphenazine (50) |
| Schizophrenia  | M    | 55   | 21.40| 6.51 | Yes    | Myocardial infarction      | Perphenazine     |
| Schizophrenia  | F    | 67   | 21.80| 5.80 | Unknown| Pulmonary disease          | Thioridazine, prochlorperazine (200) |
| Schizophrenia  | F    | 55   | 22.00| 5.90 | Yes    | Cancer                     | Clozapine, olanzapine (350) |
| Schizophrenia  | M    | 36   | 17.97| 6.45 | Unknown| Cardiac arrest              | Clozapine        |
| Schizophrenia  | M    | 62   | 10.75| 6.50 | Yes    | Chronic obstructive pulmonary disease, lung cancer | Clozapine       |
| Schizophrenia  | F    | 92   | 17.80| 6.34 | Unknown| Cardiomyopathy             | Unknown          |
| Schizophrenia  | M    | 56   | 21.83| 6.75 | No     | Car accident               | Olanzapine (150) |
| Schizophrenia  | F    | 88   | 13.33| 6.65 | No     | Unknown                    | Thiothixene (50) |
| Mean ± SEM     | 4M/5F| 68.11±6.60 | 16.90±1.85 | 6.34±0.11 |  |

aF = female; M = male.
bAge is given in years.
cPMI = postmortem interval in hours.
dN/A = not applicable; numbers in parentheses indicate CED.

by the Experion HighSens LabChip (Bio-Rad, Hercules, CA), although in a minority of cases the amount of total RNA was too small for this analysis (Table 2).

RNA extracted from laser-captured neurons underwent two rounds of linear amplification using the RiboAmp kit (Life Technologies) to obtain amplified (a)RNA. A dilution of the resulting products (approximately 250 ng/μL) was used to determine the distribution of transcript lengths with the Experion StdSens Labchip (Bio-Rad; Figure 1). The concentration and purity of these samples were determined by absorbance measurements at the optical density of A260 and A280, using a NanoDrop spectrophotometer (Thermo Scientific, Tewksbury, MA) (Table 2).

Microarray and qRT-PCR Validation

The TURBO Biotin labeling kit (end-labeling; Life Technologies) was used to label the aRNA obtained from amplified samples (~15 μg). Gene expression profiling was performed using the Affymetrix Human X3P GeneChip®), which possesses an extreme 3' bias in its probe design and hence is particularly suitable for samples that are prone to RNA degradation, such as postmortem human brain tissue. This chip has also been shown to be superior to the more commonly used Affymetrix human U133 plus 2.0 chip in terms of data reproducibility (Caretti et al., 2008). The hybridization and scanning procedures were performed at the Partners HealthCare Center for Personalized Genetic Medicine, Cambridge, Massachusetts. Briefly, target labeling was performed using the Message-AMP Biotin Enhanced Kit (Life Technologies). Fifteen micromgrams of biotinylated RNA was fragmented, hybridized to GeneChips, stained with two rounds of streptavidinphycoerythrin (Molecular Probes, Eugene, OR) and one round of biotinylated anti-streptavidin antibody (Vector Laboratories, Burlingame, CA), scanned twice, and inspected for hybridization artifacts before proceeding to data normalization and analysis.

For validation of microarray data, cDNA was reverse transcribed from aRNA (200 ng input) using the High Capacity RNA-to-cDNA kit (Applied Biosystems). TaqMan®-based qRT-PCR (Applied Biosystems) was subsequently performed on selected differentially expressed genes within signaling pathways identified by pathway analysis as dysregulated in schizophrenia and several randomly chosen genes (Supplementary Table 1; available online at http://informahealthcare.com/doi/abs/10.3109/01677063.2014.882918). Samples were normalized with respect to the housekeeping gene, hypoxanthine guanine phosphoribosyltransferase (HPRT), which has been shown to produce reliable results in human brain tissue as its expression does not appear to differ in disease states (Radonic et al., 2004). Normalization was performed against only one gene because of the limited quantity of RNA available from laser-captured samples. Negative controls (negative reverse transcription
and no template controls) were performed to detect any contamination of the samples, such as genomic (g)DNA. Where necessary, samples were treated with Turbo DNA-free kit (Applied Biosystems) and the negative controls repeated to confirm gDNA removal before qRT-PCR was performed. Samples were run in duplicate. If the difference between the duplicates exceeded 0.5 \( \Delta C_t \) (threshold cycle), the samples were repeated. The average of the duplicates was taken as input for quantification using the \( 2^{-\Delta C_t} \) method (Livak & Schmittgen, 2001) or the relative expression software tool (REST) for group-wise comparisons of expression ratios (Pfaffl et al., 2002). A Spearman’s rho correlation analysis was then performed on the fold-changes determined by microarray and qRT-PCR. In accordance with Morey et al. (2006), a correlation of \( >0.8 \) with a significance of \( p < 0.05 \) between qRT-PCR and microarray expression changes was considered validation of the microarray result.

**miRNA Profiling Using Megaplex miRNA TaqMan Arrays**

Total RNA was extracted from \( \sim 100 \) laser-captured cells with the mirVana miRNA Detection Kit (Life Technologies). This typically resulted in approximately 4–7 ng of total RNA (Table 2). The concentration and purity of the total RNA were determined by a NanoDrop spectrophotometer, as described above. miRNA profiling was conducted according to manufacturer’s specifications (Supplementary Methods 1 available online at http://informahealthcare.com/doi/abs/10.3109/01677063.2014.882918).

**Data Analysis**

**Microarray Data Analysis**

Each array was scanned twice and the Affymetrix Microarray Suite 5.1 software averaged the two images to compute an intensity value for each probe cell within each probe set. For the quality control step, we employed the dChip and Partek software’s built-in function (Partek, St. Louis, MO). We then normalized the data with Partek’s standard normalization method (i.e., data have a mean of 0 and a variance of 1, and each column for each sample was divided by the average of all control samples). Principal component analysis revealed the contribution

---

**Figure 1.** Identification of pyramidal neurons and LCM procedure. Photomicrograph of a pyramidal neuron in the STG visualized with Histogene stain (A). After identification (B), pyramidal neurons are captured (C) onto the LCM cap (D). (E) Representative virtual gels showing the distribution of sizes of amplified products after two rounds of linear amplification of RNA extracted from \( \sim 500 \) pyramidal neurons from a normal control (C) and a schizophrenia (S) subject. L = ladder. (F) Heatmap of 1331 differentially expressed genes identified based on the stringency criteria of fold-change > 1.1 and FDR-corrected \( p < 0.05 \). Scale bars = 25 \( \mu \)m.
of batch effect (i.e., scan date), but not sex, age, PMI,
or antipsychotic treatment, to the observed expression
variance. As such, an analysis of covariance (ANCOVA)
was performed with batch effect as covariate (Simunovic
et al., 2009). Differentially expressed genes were visual-
ized by performing unsupervised hierarchical clustering
as stringency of the fi ltering criteria (i.e., fold-change
and false discovery rate [FDR]-adjusted p-value) was
varied to determine a representative gene list for pathway
analyses.

We employed three approaches to explore the bio-
logical significance of our expression data. First, dif-
ferentially expressed genes were manually grouped to
elucidate gene families that were dysregulated in schizo-
phrenia. Second, pathway analyses were performed with
two Web-based algorithms, Ingenuity Pathway Analysis
(Ingenuity Systems, Redwood City, CA) and MetaCore
(GeneGo, Carsbad, CA), to map the differentially
expressed genes onto biological functions and canonical
paths. With Ingenuity, the significance for each of the identified pathways was determined via a Fisher’s
exact test, whereas GeneGo Metacore makes use of their
algorithm for hypergeometric distribution, identifying
paths overrepresented with significant genes. Third,
literature mining was performed to elucidate which of
these pathways or gene families might be particularly
pertinent for pyramidal neuronal functions and dendritic/
synaptic architecture and plasticity. We also made note
of differentially expressed genes that have been implicated
as schizophrenia risk genes (Allen et al., 2008).

Microarray data have been deposited into the Gene
Expression Omnibus (GEO; http://www.ncbi.nlm.nih.
gov/projects/geo/; accession number GSE37981).

miRNA Data Analysis

Primary analysis of the acquired signal data was performed
in SDS and RQ Manager (Applied Biosystems). Quality
control and differential expression analyses were performed
using the qRT-PCR package for miRNA arrays (Applied
Biosystems) in Bioconductor (www.bioconductor.org).
The databases used to identify potential miRNA targets
for specific miRNAs are summarized in Supplementary
Methods 2 available online at http://informahealthcare.
com/doi/abs/10.3109/01677063.2014.882918. Significant
enrichment of specific Gene Ontology categories or KEGG
(Kyoto Encyclopedia of Genes) pathways was estimated
by hypergeometric tests or chi-square tests. Enriched path-
ways overrepresented by potential miRNA target genes
were then determined with the p-value obtained by hyper-
geometric tests and adjusted for multiple comparisons
(Kanehisa & Goto, 2000; Kanehisa et al., 2006, 2010).

Table 2. RNA quantity and quality.

| Group            | RIN of total RNA extracted from homogenized cortex\(a\) | Number of cells captured | Total RNA RQI\(b\) | Amount of RNA before/after amplification (\(\mu g\)) | A260/A280 |
|------------------|-------------------------------------------------------|--------------------------|--------------------|---------------------------------------------------|-----------|
| Control          | 8.2                                                   | 510                      | 2.6                | 0.025/39.50                                       | 2.67      |
| Control          | 7.9                                                   | 530                      | N/A                | 0.004/69.30                                       | 2.37      |
| Control          | 8.9                                                   | 520                      | 3.1                | 0.014/54.30                                       | 2.44      |
| Control          | 8.8                                                   | 500                      | 2.8                | 0.004/39.49                                       | 2.51      |
| Control          | 7.8                                                   | 680                      | 3.4                | 0.007/50.10                                       | 2.39      |
| Control          | 9                                                     | 600                      | 3.7                | 0.009/59.92                                       | 2.54      |
| Control          | 8.4                                                   | 530                      | 2.8                | 0.012/59.60                                       | 2.47      |
| Control          | 8                                                     | 520                      | 3.6                | 0.007/29.83                                       | 2.75      |
| Control          | 8.8                                                   | 520                      | N/A                | 0.002/24.52                                       | 2.70      |
| Mean ± SD       | 8.42 ± 0.15                                           | 545.56 ± 19.30           | 3.14 ± 0.16        | 0.009 ± 0.002/40.73 ± 5.15                        | 2.54 ± 0.05|
| Schizophrenia    | 8.9                                                   | 525                      | 3.8                | 0.004/76.83                                       | 2.47      |
| Schizophrenia    | 8                                                     | 525                      | 4.2                | 0.003/65.10                                       | 2.43      |
| Schizophrenia    | 7.9                                                   | 540                      | N/A                | 0.002/62.10                                       | 2.52      |
| Schizophrenia    | 8.5                                                   | 540                      | 2.8                | 0.004/46.92                                       | 2.75      |
| Schizophrenia    | 9.2                                                   | 530                      | N/A                | 0.001/62.10                                       | 2.44      |
| Schizophrenia    | 8.5                                                   | 630                      | N/A                | 0.002/75.90                                       | 2.34      |
| Schizophrenia    | 8.2                                                   | 540                      | 3.5                | 0.003/65.68                                       | 2.50      |
| Schizophrenia    | 8.8                                                   | 700                      | 3.4                | 0.003/50.10                                       | 2.47      |
| Schizophrenia    | 8.4                                                   | 550                      | 3.4                | 0.003/52.20                                       | 2.47      |
| Mean ± SD       | 8.48 ± 0.16                                           | 564.56 ± 20.06           | 3.52 ± 0.19        | 0.002 ± 0.003/61.88 ± 3.54                        | 2.49 ± 0.04|

\(a\)RNA integrity number (RIN) of total RNA extracted from homogenized gray matter determined by an Agilent
bioanalyzer.

\(b\)RNA Quality Indication (RQI) of total RNA extracted from laser-captured neurons determined by a BioRad
Experion Automated Electrophoresis System. N/A = not available: total RNA concentration too low to determine RQI.
RESULTS

Affymetrix-Based Microarray Gene Expression Profiling

We evaluated the reliability of our findings by assessing mRNA quality based on a combination of metrics, as there is not a single parameter that can serve as the sole determinant or predictor of mRNA quality. Although the quality of the total RNA extracted from homogenized cortex from all of the subjects used in this study appears to be superb (Table 2), the RQI of most samples on average tended to be relatively low, suggesting some RNA degradation. This was expected given the significantly lengthier (i.e., compared with extracting RNA from homogenized tissue) aqueous steps required for RNA extraction from single neurons (Pietersen et al., 2009, 2011). However, although RQI is a measure of total RNA integrity, it does not necessarily predict the quality of mRNA, which constitutes only 1–3% of total RNA (Vermeulen et al., 2011). In fact, virtual gels of the amplified products generated after two rounds of linear amplification of RNA extracted from pyramidal neurons revealed very healthy spreads of transcript lengths, extending well into the 5–6 kb range (Figure 1). Furthermore, the efficiency of microarray hybridization appeared to be adequate in terms of probe intensity and percentage of present calls, and these parameters were highly comparable between the schizophrenia and control groups, with average (± SD) probe intensity being 81.8 ± 10.5 and 70.7 ± 6.2, respectively, and percent present calls 26.9 ± 2.6 and 27.5 ± 1.0, respectively. Overall, these percentages of present calls are lower than what have been reported in previously published schizophrenia microarray studies performed on RNA extracted from homogenized cortical gray matter (typically in the range of 40–45%), which contains a much greater number of RNA species in much larger quantities. Our data, however, are similar in magnitude to what was reported in a recent microarray study of laser-dissected hippocampal subfields in humans (mean ± SD = 31.8 ± 4.9) (Benes et al., 2008), a region that is cellulosically much less heterogeneous than cortical gray matter but more so than our neuronal samples, and to what was described in previous neuronal microarray studies based on laser-captured cells from clinical samples or other specimens of single cells (Luzzi et al., 2001; Mahadevappa & Warrington, 1999).

Varying the stringency criteria of fold-change and FDR-adjusted p-value resulted in several lists of differentially expressed genes (Supplementary Table 2 available online at http://informahealthcare.com/doi/abs/10.3109/01677063.2014.882918). For instance, 1331 genes were identified based on the criteria of a minimal fold-change of 1.1 and p < 0.05, whereas only 264 genes met the slightly more stringent criteria of fold-change of 1.2 and p < 0.05. As a result, the 1331 genes were used for downstream pathway analysis. Hierarchical clustering revealed that these 1331 genes appeared to be well segregated according to diagnosis (Figure 1). A complete list of these genes is shown in Supplementary Table 3 available online at http://informahealthcare.com/doi/abs/10.3109/01677063.2014.882918. The canonical pathways and functional gene networks that were found to be altered in schizophrenia included the TGF-β/BMP signaling cascades, genes that regulate cytoskeleton and dendritic morphology and ECM composition, in addition to changes in apoptosis and DNA damage canonical pathways (Tables 3a–d). A number of key genes within the pathways that were found to be significantly differentially regulated in schizophrenia (N = 6) and several randomly selected genes (N = 4) were quantified by qRT-PCR; the expression levels of these genes were significantly correlated with the microarray data (p = 0.003; Figure 2). HPRT expression level also did not differ between schizophrenia and normal control groups (Supplementary Figure 1 available online at http://informahealthcare.com/doi/abs/10.3109/01677063.2014.882918). Finally, correlation analyses between the expression of the validated genes and age, PMI, and chlorpromazine equivalent dosage (CED) revealed no association of gene expression changes with any of these parameters, consistent with PCA results showing that none of these parameters appear to significantly contribute to differential gene expression variance of the entire data set. A representative correlation with SMAD4 (signal via the mothers against decapentaplegic homologs 4), the key transcription factor upon which TGF-β and BMP signaling converges, is depicted in Supplementary Figure 2 available online at http://informahealthcare.com/doi/abs/10.3109/01677063.2014.882918.

TGF-β Superfamily Signaling Is Altered in Schizophrenia

The TGF-β superfamily of proteins consists of over thirty members (Derynck & Miyazono, 2008). Structurally they can be subdivided in three subfamilies: TGF-β, inhibins, and other proteins including BMPs and growth and differentiation factor (GDF). Together these proteins are involved in very diverse and complex cellular functions in both developing and adult systems, including the brain (Benes, 2011; Derynck & Miyazono, 2008; Massague & Gomis, 2006; Vivien & Ali, 2006). We found that the TGF-β and BMP signaling canonical pathways were highly dysregulated in schizophrenia (GeneGo: p < 0.0001), with up-regulation of several genes immediately downstream from the TGF-β1 receptor (Supplementary Table 3a, Figure 3 available online at http://informahealthcare.com/doi/abs/10.3109/01677063.2014.882918; Figure 3). This is in line with a previous postmortem study revealing an up-regulation of the TGF-β signaling cascade in the hippocampus of schizophrenia subjects (Benes et al., 2007) and is consistent with previous reports showing the
Table 3a. Significantly affected genes within TGF-β/BMP signaling pathway.

| Gene title                                                      | Gene symbol | p-Value | Fold-change (S vs. C) |
|---------------------------------------------------------------|-------------|---------|----------------------|
| bone morphogenetic protein 1                                 | BMP1        | 0.04    | -1.33                |
| bone morphogenetic protein receptor, type IA                  | BMPR1A      | 0.04    | 1.19                 |
| bone morphogenetic protein 5                                 | BMP5        | 0.04    | 1.16                 |
| bone morphogenetic protein 7                                 | BMP7        | 0.03    | 1.21                 |
| caveolin 1, caveolar protein, 22 kDa                         | CAV1        | 0.03    | 1.54                 |
| CREB-binding protein                                          | CBP         | 0.01    | 1.31                 |
| growth arrest and DNA-damage-inducible, beta                 | GADD45B     | 0.03    | 1.30                 |
| mitogen-activated protein kinase kinase 6                     | MEK6        | 0.04    | -1.14                |
| ribosomal protein S6 kinase, 90kDa, polypeptide 5             | RPS6KA5     | 0.01    | 1.11                 |
| SHC (Src homology 2 domain containing)-transforming protein 1| SHC1        | 0.03    | 1.16                 |
| SMAD family member 4                                          | SMAD4       | 0.01    | 1.19                 |
| SMAD family member 5                                          | SMAD5       | 0.02    | 1.48                 |
| SKI-like oncogene                                             | SKIL        | 0.02    | -1.15                |
| transcription factor specificity protein 1                    | SP1         | 0.03    | 1.29                 |
| X-linked inhibitor of apoptosis                                | XIAP        | 0.02    | 1.10                 |
| zinc finger, FYVE domain containing 9                        | ZFYVE9/SARA | 0.04 | 1.14                 |

*S = schizophrenia; C = control.

Table 3b. Significantly affected genes associated with extracellular matrix.

| Gene title                                                      | Gene symbol | p-Value | Fold-change (S vs. C) |
|---------------------------------------------------------------|-------------|---------|----------------------|
| aggrecan                                                      | ACAN        | 0.03    | -1.26                |
| ADAM metalloproteinase with thrombospondin type 1 motif, 1    | ADAMTS1     | 0.03    | 2.56                 |
| ADAM metalloproteinase with thrombospondin type 1 motif, 6    | ADAMTS6     | 0.05    | 1.15                 |
| hyaluronan and proteoglycan link protein 1                    | HAPLN1      | 0.05    | -1.14                |
| leucine proline-enriched proteoglycan (leprecan) 1            | LEPRE1      | 0.04    | -1.21                |
| lumican                                                       | LUM         | 0.03    | -1.12                |
| matrix metalloproteinase 16 (membrane-inserted)              | MMP16       | 0.02    | -1.17                |
| matrix metalloproteinase 25                                   | MMP25       | 0.02    | -1.14                |
| matrix metalloproteinase 24 (membrane-inserted)              | MMP24       | 0.01    | 1.22                 |
| sperm adhesion molecule 1 (PH-20 hyaluronidase, zona pellucida binding) | SPAM1 | 0.04 | 1.15 |
| sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 3 | SPOCK3 | 0.01 | 1.11 |
| spondin 1, extracellular matrix protein                       | SPON1       | 0.02    | 2.14                 |
| versican                                                      | VCAN        | 0.04    | -1.13                |

*S = schizophrenia; C = control.

Table 3c. Significantly affected genes associated with apoptosis and DNA damage.

| Gene title                                                      | Gene symbol | p-Value | Fold-change (S vs. C) |
|---------------------------------------------------------------|-------------|---------|----------------------|
| Apoptosis and survival_BAD phosphorylation                    | EGFR        | 0.02    | 1.59                 |
| epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) | PIK3R2 | 0.04 | 1.23 |
| phosphoinositide-3-kinase, regulatory subunit 2 (beta)        | PRKACG      | 0.02    | 1.25                 |
| protein kinase, cAMP-dependent, catalytic, gamma              | PTPN11      | 0.03    | -1.11                |
| protein tyrosine phosphatase, non-receptor type 11            | SHC1        | 0.03    | 1.16                 |
| SHC (Src homology 2 domain containing)-transforming protein 1| SHC1        | 0.03    | 1.16                 |
| DNA damage_Role of SUMO in p53 regulation                     | CBP         | 0.01    | 1.31                 |
| CREB-binding protein                                          | CBP         | 0.01    | 1.31                 |
| SMT3 suppressor of mit two 3 homolog 1 (S. cervisiae)         | SUMO-1      | 0.03    | 1.17                 |
| ubiquitin-like modifier activating enzyme 1                   | UBA1        | 0.04    | 1.14                 |
| Other genes involved in DNA damage and oxidative stress       |             |         |                      |
| HLA-B (major histocompatibility complex, class I, B)-associated transcript 3 | BAT3/BAG6 | 0.01 | -1.21 |
| calpain 9                                                     | CAPN9       | 0.05    | 1.15                 |
| calpain 10                                                    | CAPN10      | 0.02    | 1.14                 |
| clusterin                                                    | CLU         | 0.02    | 2.02                 |

*S = schizophrenia; C = control.
involvement of TGF-β signaling in the pathophysiology of schizophrenia in general (Miller et al., 2011). Within the TGF-β superfamily, we found that the canonical BMP signaling pathway was significantly affected (Ingenuity: p < 0.003; GeneGo: p < 0.005) (Table 3a). Specifically, we observed an up-regulation of BMP7 and BMP receptor IA (BMPRIA), in addition to changes in genes further downstream in the signaling cascade (Figures 3 and Supplementary Figure 3 available online at http://informahealthcare.com/doi/abs/10.3109/01677063.2014.882918). Both the TFG-β and BMP canonical pathways propagate their signal via SMADs (Shi & Massague, 2003) (Figures 3 and Supplementary Figure 3 available online at http://informahealthcare.com/doi/abs/10.3109/01677063.2014.882918) and we found that SMAD4 and SMAD5 were up-regulated in schizophrenia. SMAD4 is the central mediator of both of these signal transduction cascades and regulates the transcription of target genes (Ross & Hill, 2008). Furthermore, we observed an increase in the expression of cyclic adenosine monophosphate (cAMP) response element-binding protein

![Table 3d. Significantly affected genes associated with cytoskeletal and dendritic integrity.](image)

| Gene title                      | Gene symbol | p-Value | Fold-change (S vs. C) |
|---------------------------------|-------------|---------|----------------------|
| actin, gamma 2, smooth muscle, enteric | ACTG2       | 0.04    | 1.35                 |
| dystonin                        | DST         | 0.03    | 1.25                 |
| major histocompatibility complex, class I, A | HLA-A       | 0.02    | 1.86                 |
| integrin, beta 5                | ITGB5       | 0.02    | 1.51                 |
| microtubule-associated protein 1 light chain 3 gamma | MAP1LC3C    | 0.03    | 1.19                 |
| myosin IIIB                     | MYO3B       | 0.01    | 1.13                 |
| tropomodulin 3 (ubiquitous)     | TMOD3       | 0.02    | -1.14                |
| tubulin polymerization promoting protein | TPPP        | 0.03    | -1.50                |
| tubulin tyrosine ligase-like family, member 12 | TTLL12      | 0.02    | 1.20                 |
| tubulin, alpha 4b (pseudogene)  | TUBA4B      | 0.02    | -1.17                |
| spectrin, beta, non-erythrocytic 1 | SPTBN1      | 0.05    | 1.20                 |

*S = schizophrenia; C = control.

![Figure 2. Correlation analysis comparing fold-changes of selected genes determined by microarray and qRT-PCR. Comparison of fold-changes of differentially expressed genes within signaling pathways identified as dysregulated in schizophrenia (N = 6) and several randomly selected genes (N = 4) determined by microarray and qRT-PCR. BMP7 = bone morphogenetic protein 7; BMPRIA = bone morphogenetic protein receptor type IA; CLU = clusterin; HLA-A = major histocompatibility complex (MHC), class I,A; HPRT = hypoxanthine guanine phosphoribosyl transferase; P2RY14 = purinergic receptor P2Y, G-protein coupled, 14; MCPH1 = microcephalin 1; SMAD4 = mothers against decapentaplegic homolog 4; SMAD5 = mothers against decapentaplegic homolog 5; VCAN = versican.](image)

![Figure 3. Representative diagram of TGF-β and BMP signaling pathways. Both TGF-β and BMP7 activate SMAD4 and CREB-binding protein, a transcription co-activator of SMAD, leading to the transcription of target genes that influence extracellular matrix composition, apoptosis, and synaptic/cytoskeletal plasticity. BMPRIA = bone morphogenetic protein receptor type IA; CBP = CREB-binding protein; SARA (ZFYVE9) = zinc finger, FYVE domain containing 9; SMAD4 = mothers against decapentaplegic homolog 4. Genes up-regulated in schizophrenia are depicted by red arrows.](image)
(CREB)-binding protein (CBP), a transcription co-activator of SMAD (Ohta et al., 2008). Although not part of this particular canonical pathway, we noted a down-regulation of BMP5, which also acts via the BMPR1A (Beck et al., 2001). Of interest, BMP5, BMP7, SMAD5, and CBP were all found to be significantly associated with schizophrenia in a recent genome-wide association study (Jia et al., 2010), with both TGFBI and SMAD5 implicated as potential candidate genes in a linkage study (Zaharieva et al., 2008). Finally, these pathways are known to regulate the integrity of ECM (Hyytiainen et al., 2004; Smith & Strunz, 2005; Zhou et al., 2003), apoptosis (Dhandapani & Brann, 2003), and cytoskeleton (Guo et al., 1998; Moustakas & Heldin, 2008), raising the possibility that disturbances of genes that regulate these functions (see below) may in part represent downstream consequences of dysregulated TGF-β/BMP signaling.

**ECM Regulation Is Altered in Schizophrenia**

Gene networks related to ECM functionality, including altered cellular movement (p < 0.03) and changes in adhesion to the fibronectin matrix (p < 0.05), were altered in schizophrenia (Table 3b). Specifically, a number of genes coding for chondroitin sulfate proteoglycans (CSPGs) were down-regulated. These include aggrecan, versican, leprecan, lumican, testican, and spindlin1. In addition, we found changes in genes that encode matrix metalloproteinases (MMPs), which are enzymes that are involved in the breakdown and remodeling of ECM by the proteolysis of several ECM components, including the CSPGs (Rauch, 2004). Specifically, we found an up-regulation of ADAM (a disintegrin and metalloproteinase) metalloproteinase with thrombospondin type 1 motif gene family (ADAMTS1 and ADAMTS6), in addition to alterations in several other MMPs, in the schizophrenia samples (Table 3b). Together these data suggest that the decrease in ECM structural components, such as CSPGs, in addition to the alterations in the enzymes that regulate their proteolysis, contribute to the altered integrity of ECM (Ikeda et al., 2009; Mauney et al., 2013; Pantazopoulos et al., 2010).

**Apoptosis Regulation Is Altered in Schizophrenia**

Two apoptosis canonical pathways were found to be dysregulated in schizophrenia (Table 3c). We noted predominantly an up-regulation of genes within the p53-regulated apoptosis pathway (GeneGo: p < 0.03), suggesting pro-apoptotic events (Pietsch et al., 2008), although the exact function of sumoylation of p53 remains controversial (Melchior & Hengst, 2002). We also found changes in the expression of several genes associated with oxidative stress and DNA damage (Table 3c). Conversely, we saw increased expression of anti-apoptotic genes within the BCL2 (B-cell chronic lymphocytic leukemia [CLL]/lymphoma 2)-associated agonist of cell death (BAD) apoptosis survival pathway (GeneGo: p < 0.03), which inhibits apoptosis through BAD phosphorylation (Bergmann, 2002). Interestingly, TGF-β signaling regulates BAD phosphorylation via the induction of anti-apoptotic proteins of the BCL-2 family (E. S. Kim et al., 1998). Together these results appear to reflect the complex interplay between the orchestrated molecular responses regulating apoptosis that may in part be mediated by TGF-β signaling.

**Cytoskeletal Regulation Is Altered in Schizophrenia**

We found significant alterations in key biological functions (Ingenuity) related to the integrity of cytoskeleton. This included the organization of actin cytoskeleton (p < 0.05) and actin filaments (p < 0.05), coalignment of neurofilaments and microfilaments (p < 0.05) and redistribution of F-actin (p < 0.05). We also noted changes in genes encoding cytoskeletal components, such as tubulin and myosin (Table 3d). Finally, we observed that the integrin β5 receptor was up-regulated in schizophrenia. Integrin signaling is the major signaling pathway that mediates the interaction between ECM and the assembly of actin filaments that is necessary for cytoskeletal modification (Giancotti & Ruoslahti, 1999; Shi & Ethell, 2006; Wozniak et al., 2004).

**miRNA Profiling by Megaplex miRNA TaqMan Arrays**

miRNA expression levels were normalized to the endogenous sno-RNA MammU6, whose levels were unchanged between control and schizophrenia samples for both the Human miRNA A and B Cards (mean ± SEM: 30.63 ± 0.35 and 31.72 ± 0.72, respectively). Out of the 754 miRNAs investigated, analysis of variance (ANOVA) revealed 10 differentially expressed miRNAs (p < 0.05; Table 4). Many of these miRNAs are known to be expressed in the brain (Baskerville & Bartel, 2005; Landgraf et al., 2007), with some identified as being specifically localized in mammalian cortical neurons (e.g., miR-30b and miR-328) (J. Kim et al., 2004). A number of the differentially expressed miRNAs also correspond with previous studies on postmortem schizophrenia samples, including miR-150 (J. Kim et al., 2004), miR-328 (Santarelli et al., 2011), and miR-30b (Mellios et al., 2012; Perkins et al., 2007), with the caveat that all of the previously published miRNA profiling results were based on RNAs extracted from homogenized gray matter. Interestingly, enrichment analysis of the predicted target genes of the differentially expressed miRNAs revealed that the overrepresented signaling pathways included...
many of the pathways identified by microarray as differentially regulated in schizophrenia, such as TGF-β signaling, ECM composition, apoptosis, and cytoskeleton (Table 5, Supplementary Table 3 available online at http://informahealthcare.com/doi/abs/10.3109/01677063.2014.882918). The specific genes that were found by microarray to be differentially expressed in schizophrenia and are also the predicted targets of the differentially expressed miRNAs are shown in Supplementary Table 4 available online at http://informahealthcare.com/doi/abs/10.3109/01677063.2014.882918.

**DISCUSSION**

In order to understand the pathophysiology of schizophrenia, which is a manifestation of functional disturbances of cortical circuits characterized by neuronal type-dependent connectional complexity, it is necessary to define the molecular pathology of the illness in a neuronal type-specific manner. In this context, previous gene expression profiling studies of the cerebral cortex in schizophrenia have largely relied on the extraction of RNA from homogenized gray matter. Interpretation of these results can be difficult due to the profound cellular heterogeneity of the cerebral cortex, as gene expression changes that may be confined to a subset of neurons can be obscured, especially if transcript abundance is low or if specific transcripts are preferentially localized to cell types that are relatively uncommon. In this study, by combining LCM with mRNA profiling, we circumvented these potential problems and identified molecular cascades that appear to be dysregulated in layer 3 pyramidal neurons in the STG in schizophrenia. Specifically, our data revealed that a number of genes within the TGF-β superfamily, especially those that regulate BMP signaling, were differentially expressed in subjects with schizophrenia. In addition, we identified abnormalities in genes that regulate apoptosis, cytoskeletal plasticity, and ECM, that may, at least in part, represent downstream consequences of TGF-β signaling dysregulation. We should also note that the majority (61%) of these genes, with some exceptions, such as those that regulate ECM, were found to be up-regulated. In contrast, previous studies interrogating the expression of mRNA extracted from homogenized gray matter have revealed an overall decrease in gene expression (Iwamoto & Kato, 2006), and, for the most part, these genes do not overlap with genes identified in the present study. These differential findings, in our opinion, highlight the argument that neuronal type-specific gene expression alterations and thus the molecular pathophysiology of the illness in terms of cortical neuronal circuit dysfunction cannot necessarily be inferred from the interrogation of expression of transcripts obtained from homogenized cortical tissue. In more specific quantitative terms, approximately 84% of the volume of the cortex, excluding layer 1, contains glia, neuropil, which comprises axonal elements, dendrites and dendritic spines, and vascular elements such as blood vessels and related cellular components, including endothelial cells and various blood cells (Braitenberg & Schuz, 1998), and the abundance of many transcripts can vary in a compartment-specific manner (Cajigas et al., 2012). Of the remaining 16% of the volume that contains neuronal bodies in layers 2–6, approximately 80% of them are pyramidal neurons and roughly 16% (i.e., 80% divided by 5 layers) are from layer 3. In other words, layer 3 pyramidal neurons represent only about 3% (i.e., 16% times 16%) of the entire volume of cortical gray matter. As such, it is difficult to envision that gene expression changes that may be restricted to this neuronal population can be readily discerned by studying RNA obtained from homogenization of the entire gray matter. This would arguably be especially true for the less abundant cell types, such as the various subsets of inhibitory neurons, including those that were examined in the accompanying study, the parvalbumin (PV)-containing neurons (Pietersen et al. 2014).

**Table 4. Differentially expressed miRNAs in schizophrenia.**

| miRNA assay name | p-Value | Log₂ fold-change |
|------------------|---------|------------------|
| hsa-miR-1243-002854 | 0.03 | -0.41 |
| hsa-miR-126-4395339 | 0.03 | 1.84 |
| hsa-miR-150-4373127 | 0.05 | -0.96 |
| hsa-miR-30b-4373290 | 0.02 | 4.64 |
| hsa-miR-328-4373049 | < 0.001 | 2.82 |
| hsa-miR-378-002243 | 0.04 | -0.31 |
| hsa-miR-520d-3p-002743 | 0.01 | 0.12 |
| hsa-miR-628-5p-4395544 | 0.03 | -1.05 |
| hsa-miR-875-5p-002203 | 0.04 | -0.41 |
| hsa-miR-99b-4373007 | 0.04 | 2.77 |

**Table 5. Overrepresented KEGG pathways based on enrichment analysis of the predicted target genes of the differentially expressed miRNAs.**

| Pathway                          | Enrichment statistics           |
|----------------------------------|---------------------------------|
| TGF-β signaling pathway          | C = 155; O = 63; E = 8.75; R = 7.20; rawP = 1.27e-37; adjP = 1.45e-35 |
| Focal adhesion                   | C = 201; O = 48; E = 11.35; R = 4.23; rawP = 9.92e-18; adjP = 1.46e-16 |
| Regulation of actin cytoskeleton | C = 143; O = 37; E = 8.07; R = 4.58; rawP = 3.41e-15; adjP = 4.32e-14 |
| Apoptosis                        | C = 82; O = 20; E = 4.63; R = 4.32; rawP = 2.12e-08; adjP = 8.06e-08 |
| ECM-receptor interaction         | C = 84; O = 16; E = 4.74; R = 3.37; rawP = 1.67e-05; adjP = 4.63e-05 |
Methodological Considerations and Limitations

The goal of this study was to delineate the gene expression profile of layer 3 pyramidal neurons in schizophrenia in order to gain insight into the molecular basis of cortical circuit dysfunction. In this context, it should be noted that obtaining RNA from a truly homogeneous source from postmortem human brains, given the technologies that are available at the present time, is probably not achievable. For instance, when capturing pyramidal neurons, it would have been inevitable to include additional elements, such as the perineuronal oligodendrocytes, GABAergic axon terminals that innervate the perisomatic region of pyramidal neurons, etc. In fact, we found that the mRNA for the gene that encodes the 65-kDa isoform of the GABA-synthesizing enzyme glutamic acid decarboxylase (GAD2) was significantly down-regulated by 1.9-fold in the schizophrenia subjects (Supplementary Table 3 available online at http://informahealthcare.com/doi/abs/10.3109/01677063.2014.882918). This is not a type I error, as qRT-PCR confirmed the presence of this transcript in our samples and its down-regulation by 3.1-fold. Because GAD2 is clearly not expressed in pyramidal neurons and because our sampling approach excludes the possibility of systematic inclusion of GABAergic neurons in our samples, the GAD2 mRNA in the samples most likely came from the GABAergic axon terminals innervating the pyramidal cell bodies. However, definitive confirmation of the presence of mRNA in axonal terminals in the human brain would be technically challenging.

Another consideration is that due to the labor-intensive nature of this methodological approach and the associated costs, the sample size of this study is small. This may have increased the likelihood of type II error. Although to a certain extent type I error can be addressed by means of validation (e.g., by qRT-PCR), type II error can only be minimized by increasing sample size. Finally, because the amount of RNA available for each sample was limited, the number of genes we were able to validate by qRT-PCR is small. For the same reason, we only used one housekeeping gene for normalization and samples were run in duplicate instead of triplicate. Because of these limitations and caveats, we consider this study proof-of-principle and our findings preliminary; it would therefore be critical to confirm these findings in a different and ideally larger cohort of subjects in future studies. Ultimately, true validation of microarray observations will have to be achieved by experimentally demonstrating mechanistic links between the disturbances of genes and pathways identified as altered in schizophrenia and known cellular and clinical phenotypes of the illness, such as decreased spine density on pyramidal neurons (Glantz & Lewis, 2000; Sweet et al., 2009) or disturbances of ECM integrity (Pantazopoulos et al., 2010), and neurocognitive deficits (Barch et al., 2003; Bowie & Harvey, 2005; Cho et al., 2006) or gamma oscillation disturbances (Cho et al., 2006; Kwon et al., 1999; Spencer et al., 2004; Uhlhaas & Singer, 2010), respectively. In fact, this is exactly how postmortem microarray studies can uniquely contribute to the understanding of the pathophysiology of human psychiatric disorders; that is, they can inspire the conceptualization of novel hypotheses of disease mechanisms that can then be experimentally interrogated either in vitro or in animal systems.

Functional Considerations of Up-regulation of TGF-β and BMP Signaling in Schizophrenia

Apoptosis and Dendritic Atrophy

Up-regulation of TGF-β signaling typically represents a homeostatic response under a wide variety of pathological conditions, such as excitotoxicity (Chou et al., 2006; Dhandapani & Brann, 2003; Gabriel et al., 2003; Klempt et al., 1992; Petegnief et al., 2003). In schizophrenia, there has been compelling evidence indicating that the PV-containing fast-spiking inhibitory neurons, which confer perisomatic and axo-axonic inhibition to pyramidal neurons, are functionally disturbed (Lewis et al., 2005). Specifically, inhibition furnished by these neurons may be deficient, as the mRNA for the 67-kDa isoform of the GABA-synthesizing enzyme (GAD1) appears to be undetectable in close to half of the populations of PV neurons in schizophrenia (Hashimoto et al., 2003). In addition, the expression of the N-methyl-D-aspartate (NMDA) glutamate receptor NR2A subunit mRNA in some of these neurons has also been shown to be significantly decreased (Bitanihirwe et al., 2009), suggesting that excitatory inputs to PV neurons may also be impaired. Together these findings support the idea that pyramidal neurons that are postsynaptic to PV neurons may become hyperactive as a result of disinhibition of PV neurons (Homayoun & Moghadam, 2007; Kinney et al., 2006; Olney & Farber, 1995). In this context, the observed up-regulation of TGF-β signaling may represent a homeostatic or neuroprotective response of pyramidal neurons to such excitotoxic insult (Figure 4) (Gabriel et al., 2003; Petegnief et al., 2003). One mechanism that TGF-β signaling could exert homeostatic effects is through the regulation of BAD phosphorylation pathway via the induction of anti-apoptotic proteins of the BCL-2 family (E. S. Kim et al., 1998; Prehn et al., 1994). In line with other postmortem studies indicating increased expression of anti-apoptotic genes in schizophrenia, such as BCL-2 (Benes, 2006; Benes et al., 2006), we also noted in our study an up-regulation of several genes within this pathway. Conversely, although we found an up-regulation of several pro-apoptotic genes within the p53-regulated pro-apoptosis pathway, e.g., SUMO-1 (small ubiquitin
related modifier precursor), UBA1 (ubiquitin-like modifier activating enzyme 1), and CBP, expression of TP53, which encodes p53, the key initiator of apoptosis, was unaltered.

Although large-scale pyramidal cell death does not occur in schizophrenia, “nonlethal” apoptosis can lead to neuronal injury in the form of dendritic atrophy (Glantz et al., 2006). For example, chronic glutamate excess has been shown to lead to a 20% reduction in primary dendritic length without causing cell death (Esquenazi et al., 2002). The integrity of dendritic architecture depends on coordinated activities of various cytoskeletal components (Svitkina et al., 2010). Our results indicate that several cytoskeletal genes, including actin, tubulin, and microtubules, are dysregulated in schizophrenia. BMP signaling, particularly BMP7, has also been shown to affect dendrite formation in cortical neurons (Guo et al., 1998; Horbinski et al., 2002; Le Roux et al., 1999), through both the remodeling of the actin cytoskeleton (Lee-Hoeflich et al., 2004) and the stabilization of microtubules (Podkowa et al., 2010). Of interest, BMP7 has also been shown to attenuate the reduction of primary dendrites exposed to glutamate excitotoxicity, suggesting a neuroprotective response (Esquenazi et al., 2002).

Considering all of these findings together, up-regulation of TGF-β/BMP signaling may represent a molecular snapshot of the internal homeostasis of these neurons in response to disinhibition-induced excitotoxic injury.

ECM Disturbances

CSPGs are critical components of perineuronal nets (PNNs) (Figure 5A), which are ECM structures that enwrap the cell body and perisomatic region of various types of neurons, including PV and pyramidal neurons (Frischknecht & Seidenbecher, 2008). They are believed to originate predominantly from glial cells and are secreted into the extracellular space (Morgenstern et al., 2002; Pantazopoulos et al., 2008). Using biotin-labeled lectin from Wisteria floribunda agglutinin (WFA) to label CSPGs, it has recently been found that, in the human amygdala, CSPG-containing cells were virtually exclusively astrocytes (Pantazopoulos et al., 2008, 2010). At the same time, the density of PNNs in the amygdala has been found to be significantly decreased in schizophrenia (Pantazopoulos et al., 2010), which may be a result of impaired secretion and/or production of CSPGs by astrocytes (Pantazopoulos et al., 2010). In the present study, however, our data indicate that the transcripts of many of the genes that encode CSPGs are present in pyramidal neurons in the STG. Consistent with this, it has recently been shown that one of the CSPGs, versican, is localized to the somata and dendrites of pyramidal neurons in the mouse cerebral cortex (Horii-Hayashi et al., 2008). Cell culture studies have also shown that the production of some of the CSPGs, such as aggregan, may be glia independent (Giamanco & Matthews, 2012). Furthermore, using WFA histochemistry, we have found that many of the cells that express CSPGs in the human cerebral cortex appear to be neurons, not astrocytes (Ikeda et al., 2009) (Figure 5B). Hence, cellular mechanisms of CSPG production and/or secretion may differ between the cortex and subcortical structures. In the present study, we found that many of the CSPG transcripts in

Figure 5. Wisteria floribunda agglutinin (WFA) histochemical labeling of chondroitin sulfate proteoglycans (CSPGs) in the human cerebral cortex. (A) CSPG-rich perineuronal nets (arrowheads). (B) WFA also labeled intracellular CSPGs (arrowhead). Scale bars = 5 μm (A and B).
Pyramidal Neurons in Schizophrenia

Pyramidal neurons were significantly down-regulated in schizophrenia (Table 3b). Consistent with this observation and the aforementioned finding in the amygdala (Pantazopoulos et al., 2010), the density of PNNs in the prefrontal cortex has also been found to be decreased in schizophrenia (Mauney et al., 2013). A decrease in PNNs may render synaptic structures more vulnerable to alterations, contributing to reduced synaptic connectivity. It is of interest to note that TGF-β signaling is known to play a key role in regulating CSPGs (Asher et al., 2002). However, activation of TGF-β signaling typically leads to increased CSPG production (Asher et al., 2000, 2002), but we observed primarily a down-regulation of CSPG mRNAs. Further investigation is therefore needed to elucidate the precise relationship, if any, between the up-regulation of TGF-β signaling and the dysregulation of CSPGs in schizophrenia.

Altered miRNA Expression in Schizophrenia

In addition to alterations in gene expression and biological pathways, we also noted changes in the posttranscriptional regulatory environment, characterized by alterations in miRNA expression. The number of miRNAs identified in this study is relatively small, but in the same order of magnitude as found in previous studies investigating miRNA expression in the cerebral cortex in schizophrenia (Beveridge et al., 2008; Moreau et al., 2011; Santarelli et al., 2011). However, direct comparison of our data with those of the previous studies may not be appropriate, as all of these studies examined RNA extracted from homogenized cortical gray matter.

Results of pathway analysis of the predicted target genes of the differentially expressed miRNAs correlate highly with the dysregulated biological pathways identified by mRNA expression profiling, such as TGF-β signaling, regulation of actin cytoskeleton, ECM-receptor interaction, and apoptosis (Table 5), in addition to other pathways that have also been associated with schizophrenia, such as mitogen-activated protein kinase (MAPK) signaling, neurotrophin signaling, axon guidance, and WNT signaling. These data raise an intriguing possibility that the pathophysiology of pyramidal cell dysfunction in schizophrenia may in part be mediated by the concerted dysregulation of gene network functions as a result of the altered expression of a relatively small number of miRNAs.

CONCLUSION

We have identified molecular pathways that appear to be altered in layer 3 pyramidal neurons in the STG in schizophrenia. These findings provide a neurobiological foundation upon which experimental manipulation of the expression of the differentially expressed genes may allow us to begin to characterize the molecular architectures that underlie pyramidal cell dysfunction in schizophrenia. For instance, based on our findings, one might hypothesize that neurons derived from induced pluripotent stem cells from patients with schizophrenia may be particularly vulnerable to oxidative stress, which may then lead to dysregulated TGF-β/BMP signaling and downstream consequences, such as compromised extracellular matrix, hypoplastic dendritic spines, etc. An alternative approach may involve overexpressing genes related to the TGF-β/BMP pathway using pyramidal cell–specific promoters in in vivo systems to see if this may result in similar molecular pathologies. Hence, this “reverse translational strategy” circumvents the traditional difficulties of studying the biology of psychiatric disorders due to the inaccessibility of the living human brain and may ultimately lead to deeper understanding of the pathogenetic mechanisms of these devastating, uniquely human disorders.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

This study was supported by grants P50MH080272 (Boston CIDAR: Vulnerability to Progression in Schizophrenia) and R01MH076060 from the National Institutes of Health.

REFERENCES

Allen, N. C., Bagade, S., McQueen, M. B., Ioannidis, J. P., Kavvoura, F. K., Khoury, M. J., et al. (2008). Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: The SzGene database. Nat Genet, 40, 827–834.

Ananth, H., Popescu, I., Critchley, H. D., Good, C. D., Frackowiak, R. S., & Dolan, R. J. (2002). Cortical and subcortical gray matter abnormalities in schizophrenia determined through structural magnetic resonance imaging with optimized volumetric voxel-based morphometry. Am J Psychiatry, 159, 1497–1505.

Armsten, A. F., Paspalas, C. D., Gamo, N. J., Yang, Y., & Wang, M. (2010). Dynamic Network Connectivity: A new form of neuroplasticity. Trends Cogn Sci, 14, 365–375.

Asher, R. A., Morgenstern, D. A., Fidler, P. S., Adcock, K. H., Oohira, A., Braistead, J. E., et al. (2000). Neurocan is upregulated in injured brain and in cytokine-treated astrocytes. J Neurosci, 20, 2427–2438.

Asher, R. A., Morgenstern, D. A., Shearer, M. C., Adcock, K. H., Pesheva, P., & Fawcett, J. W. (2002). Versican is upregulated in CNS injury and is a product of oligodendrocyte lineage cells. J Neurosci, 22, 2225–2236.

Barch, D. M., Sheline, Y. I., Csernansky, J. G., & Snyder, A. Z. (2003). Working memory and prefrontal
cortex dysfunction: Specificity to schizophrenia compared with major depression. *Biol Psychiatry*, 53, 376–384.

Baskerville, S., & Bartel, D. P. (2005). Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. *RNA*, 11, 241–247.

Beck, H. N., Drahushuk, K., Jacoby, D. B., Higgins, D., & Lein, P. J. (2001). Bone morphogenetic protein-5 (BMP-5) promotes dendritic growth in cultured sympathetic neurons. *BMC Neurosci*, 2, 12.

Benes, F. M. (2006). Strategies for improving sensitivity of gene expression profiling: Regulation of apoptosis in the limbic lobe of schizophrenics and bipolars. *Prog Brain Res.*, 158, 153–172.

Benes, F. M. (2011). Regulation of cell cycle and DNA repair in post-mitotic GABA neurons in psychotic disorders. *Neuropsychopharmacology*, 60, 1232–1242.

Benes, F. M., Lim, B., Matzilevich, D., Subburaju, S., & Walsh, J. P. (2008). Circuitry-based gene expression profiles in GABA cells of the trisynaptic pathway in schizophrenics versus bipolars. *Proc Natl Acad Sci U S A*, 105, 20935–20940.

Benes, F. M., Lim, B., Matzilevich, D., Walsh, J. P., Subburaju, S., & Minns, M. (2007). Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. *Proc Natl Acad Sci U S A*, 104, 10164–10169.

Benes, F. M., Matzilevich, D., Burke, R. E., & Walsh, J. (2006). The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia. *Mol Psychiatry*, 11, 241–251.

Bergmann, A. (2002). Survival signaling goes BAD. *Dev Cell*, 3, 607–608.

Beveridge, N. J., Tooney, P. A., Carroll, A. P., Gardiner, E., Bowden, N., Scott, R. J., et al. (2008). Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. *Hum Mol Genet*, 17, 1156–1168.

Bitanhirwe, B. K., Lim, M. P., Kelley, J. F., Kaneko, T., & Woo, T.-U. W. (2009). Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia. *BMC Psychiatry*, 9, 71.

Bowie, C. R., & Harvey, P. D. (2005). Cognition in schizophrenia: Impairments, determinants, and functional importance. *Psychiatr Clin North Am*, 28, 613–632, 626.

Braitenberg, V., & Schuz, A. (1998). *Cortex: Statistics and geometry of neuronal connectivity*. Berlin: Springer.

Buzsaki, G., & Draguhn, A. (2004). Neuronal oscillations in cortical networks. *Science*, 304, 1926–1929.

Cajigas, I. J., Tushev, G., Will, T. J., tom Dieck, S., Fuerst, N., & Schuman, E. M. (2012). The local transcriptome in the synaptic neuropil revealed by deep sequencing and high-resolution imaging. *Neuron*, 74, 453–466.

Caretti, E., Devarajan, K., Coudry, R., Ross, E., Clapper, M. L., Cooper, H. S., et al. (2008). Comparison of RNA amplification methods and chip platforms for microarray analysis of samples processed by laser capture microdissection. *J Cell Biochem*, 103, 556–563.

Cascella, N. G., Fieldstone, S. C., Rao, V. A., Pearlson, G. D., Sawa, A., & Schretlen, D. J. (2010). Gray-matter abnormalities in deficit schizophrenia. *Schizophr Res*, 120, 63–70.

Cho, R. Y., Konecky, R. O., & Carter, C. S. (2006). Impairments in frontal cortical [gamma] synchrony and cognitive control in schizophrenia. *Proc Natl Acad Sci U S A*, 103, 19878–19883.

Chou, J., Harvey, B. K., Chang, C. F., Shen, H., Morales, M., & Wang, Y. (2006). Neuroregenerative effects of BMP7 after stroke in rats. *J Neurosci*, 240, 21–29.

Costa, E., Davis, J., Grayson, D. R., Guidotti, A., Pappas, G. D., & Pesold, C. (2001). Dendritic spine hypoplasticity and downregulation of reelin and GABAergic tone in schizophrenia vulnerability. *Neurobiol Dis*, 8, 723–742.

Derynck, R., & Miyazono, K. O. (2008). The TGF-[beta] family. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.

Dhandapani, K. M., & Brann, D. W. (2003). Transforming growth factor-beta: A neuroprotective factor in cerebral ischemia. *Cell Biochem Biophys*, 39, 13–22.

Esquenazi, S., Monnerie, H., Kaplan, P., & Le Roux, P. (2002). BMP-7 and excess glutamate: Opposing effects on dendrite growth from cerebral cortical neurons in vitro. *Exp Neurol*, 176, 41–54.

Frischknecht, R., & Seidenbecher, C. I. (2008). The crosstalk of hyaluronan-based extracellular matrix and synapses. *Neuron Glia Biol*, 4, 249–257.

Gabriel, C., Ali, C., Lesne, S., Fernandez-Monreal, M., Docagne, F., Flawinski, L., et al. (2003). Transforming growth factor alpha-induced expression of type I plasminogen activator inhibitor in astrocytes rescues neurons from excitotoxicity. *FASEB J*, 17, 277–279.

Garey, L. J., Ong, W. Y., Patel, T. S., Kanani, M., Davis, A., Mortimer, A. M., et al. (1998). Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. *J Neurol Neurosurg Psychiatry*, 65, 446–453.

Geschwind, D. H., Ou, J., Easterday, M. C., Dougherty, J. D., Jackson, R. L., Chen, Z., et al. (2001). A genetic analysis of neural progenitor differentiation. *Neuron*, 29, 325–339.

Giamanco, K. A., & Matthews, R. T. (2012). Deconstructing the perineuronal net: Cellular contributions and molecular composition of the neuronal extracellular matrix. *Neuroscience*, 218, 367–384.

Giancotti, F. G., & Ruoslahti, E. (1999). Integrin signaling. *Science*, 285, 1028–1032.

Glantz, L. A., Gilmore, J. H., Lieberman, J. A., & Jarok, G. L. (2006). Apoptotic mechanisms and the synaptic pathology of schizophrenia. *Schizophr Res*, 81, 47–63.

Glantz, L. A., & Lewis, D. A. (2000). Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. *Arch Gen Psychiatry*, 57, 65–73.

Guo, X., Rueger, D., & Higgins, D. (1998). Osteogenic protein-1 and related bone morphogenetic proteins regulate dendritic growth and the expression of microtubule-associated protein-2 in rat sympathetic neurons. *Neurosci Lett*, 245, 131–134.

Gur, R. E., Cowell, P. E., Latshaw, A., Turisky, B. I., Grossman, R. L., Arnold, S. E., et al. (2000). Reduced dorsal and orbital prefrontal gray matter volumes in schizophrenia. *Arch Gen Psychiatry*, 57, 761–768.
Gur, R. E., Turetsky, B. I., Bilker, W. B., & Gur, R. C. (1999). Reduced gray matter volume in schizophrenia. *Arch Gen Psychiatry*, 56, 905–911.

Hanover, J. L., Huang, Z. J., Tonegawa, S., & Stryker, M. P. (1999). Brain-derived neurotrophic factor overexpression induces precocious critical period in mouse visual cortex. *J Neurosci*, 19, RC40.

Hashimoto, T., Volk, D. W., Eggan, S. M., Mirnics, K., Pierri, J. N., Sun, Z., et al. (2003). Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. *J Neurosci*, 23, 6315–6326.

Homayoun, H., & Moghaddam, B. (2007). NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. *J Neurosci*, 27, 11496–11500.

Horbinski, C., Stachowiak, E. K., Chandrasekaran, V., Miuzukoshi, E., Higgins, D., & Stachowiak, M. K. (2002). Bone morphogenetic protein-7 stimulates initial dendritic growth in sympathetic neurons through an intracellular fibroblast growth factor signaling pathway. *J Neurochem*, 80, 54–63.

Horii-Hayashi, N., Okuda, H., Tatsumi, K., Ishizaka, S., Yoshikawa, M., & Wanaka, A. (2008). Localization of chondroitin sulfate proteoglycan versican in adult brain with special reference to large projection neurons. *Cell Tissue Res*, 334, 163–177.

Hyttiainen, M., Penttinen, C., & Kesi-Oja, J. (2004). Latent TGF-beta binding proteins: Extracellular matrix association and roles in TGF-beta activation. *Crit Rev Clin Lab Sci*, 41, 233–264.

Ikeda, M., Naitoh, M., Kubota, H., Ishiko, T., Yoshikawa, K., Yamawaki, S., et al. (2009). Elastic fiber assembly is disrupted by excessive accumulation of chondroitin sulfate in the human dermal fibrotic disease, keloid. *Biochem Biophys Res Commun*, 390, 1221–1228.

Iwamoto, K., & Kato, T. (2006). Gene expression profiling in schizophrenia and related mental disorders. *Neuroscientist*, 12, 349–361.

Jia, P., Wang, L., Meltzer, H. Y., & Zhao, Z. (2010). Common variants conferring risk of schizophrenia: A pathway analysis of GWAS data. *Schizophr Res*, 122, 38–42.

Kanehisa, M., & Goto, S. (2000). KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic Acids Res*, 28, 27–30.

Kanehisa, M., Goto, S., Furumichi, M., Tanabe, M., & Hirakawa, M. (2010). KEGG for representation and analysis of molecular networks involving diseases and drugs. *Nucleic Acids Res*, 38 (Database issue), D355–D360.

Kanehisa, M., Goto, S., Hattori, M., Akut, Kinoshi, K. F., Itoh, M., Kawashima, S., et al. (2006). From genomics to chemical genomics: New developments in KEGG. *Nucleic Acids Res*, 34 (Database issue), D354–D357.

Kim, E. S., Kim, R. S., Ren, R. F., Hawver, D. B., & Flanders, K. C. (1998). Transforming growth factor-beta inhibits apoptosis induced by beta-amyloid peptide fragment 25–35 in cultured neuronal cells. *Brain Res Mol Brain Res*, 62, 122–130.

Kim, J., Krichesky, A., Grad, Y., Hayes, G. D., Kosik, K. S., Church, G. M., et al. (2004). Identification of many microRNAs that copurify with polyribosomes in mammalian neurons. *Proc Natl Acad Sci U S A*, 101, 360–365.

Kinney, J. W., Davis, C. N., Tabarean, I., Conti, B., Bartfai, T., & Behrens, M. M. (2006). A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. *J Neurosci*, 26, 1604–1615.

Klemp, N. D., Sirimanne, E., Gunn, A. J., Klemp, M., Singh, K. H., Williams, C., et al. (1992). Hypoxia-ischemia induces transforming growth factor beta 1 mRNA in the infant rat brain. *Brain Res Mol Brain Res*, 13, 93–101.

Kwon, J. S., O’Donnell, B. F., Wallenstein, G. V., Greene, R. W., Hirayasu, Y., Nestor, P. G., et al. (1999). Gamma frequency-range abnormalities to auditory stimulation in schizophrenia. *Arch Gen Psychiatry*, 56, 1001–1005.

Landgraf, P., Rusu, M., Sheridan, R., Sewer, A., Iovino, N., Aravin, A., et al. (2007). A mammalian microRNA expression atlas based on small RNA library sequencing. *Cell*, 129, 1401–1414.

Le Roux, P., Behar, S., Higgins, D., & Charette, M. (1999). OP-1 enhances dendritic growth from cerebral cortical neurons in vitro. *Exp Neurol*, 160, 151–163.

Lee-Hoeflich, S. T., Causing, C. G., Podkowa, M., Zhao, X., Wrana, J. L., & Attisano, L. (2004). Activation of LIMK1 by binding to the BMP receptor, BMPRII, regulates BMP-dependent dendritogenesis. *EMBO J*, 23, 4792–4801.

Lewis, D. A., & Gonzalez-Burgos, G. (2008). Neuroplasticity of neocortical circuits in schizophrenia. *Neuropsychopharmacology*, 33, 141–165.

Lewis, D. A., Hashimoto, T., & Volk, D. W. (2005). Cortical inhibitory neurons and schizophrenia. *Nat Rev Neurosci*, 6, 312–324.

Livak, K. J., & Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods*, 25, 402–408.

Luzzi, V., Hoitschlag, V., & Watson, M. A. (2001). Expression profiling of ductal carcinoma in situ by laser capture microdissection and high-density oligonucleotide arrays. *Am J Pathol*, 158, 2005–2010.

Mahadevappa, M., & Warrington, J. A. (1999). A high-density probe array sample preparation method using 10- to 100-fold fewer cells. *Nat Biotechnol*, 17, 1134–1136.

Massague, J., & Gomi, R. (2006). The logic of TGFbeta signaling. *FEBS Lett*, 580, 2811–2820.

Mauney, S. A., Athanas, K. M., Pantazopoulos, H., Shaskan, N., Passeri, E., Berretta, S., et al. (2013). Developmental pattern of perineuronal nets in the human prefrontal cortex and their deficit in schizophrenia. *Biol Psychiatry*, 74, 427–435.

McCarley, R. W., Wible, C. G., Frumin, M., Hirayasu, Y., Levitt, J. J., Fischer, I. A., et al. (1999). MRI anatomy of schizophrenia. *Biol Psychiatry*, 45, 1099–1119.

Melchior, F., & Hengst, L. (2002). SUMO-1 and p53. *Tissue Res*, 630 – 6315.

Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011). Meta-analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects. *Biol Psychiatry*, 70, 663–671.
in schizophrenia: Evidence for involvement of auditory feedforward circuits. *Biol Psychiatry*, 55, 1128–1137.

Sweet, R. A., Henteleff, R. A., Zhang, W., Sampson, A. R., & Lewis, D. A. (2009). Reduced dendritic spine density in auditory cortex of subjects with schizophrenia. *Neuropsychopharmacology*, 34, 374–389.

Sweet, R. A., Pierri, J. N., Auh, S., Sampson, A. R., & Lewis, D. A. (2003). Reduced pyramidal cell somal volume in auditory association cortex of subjects with schizophrenia. *Neuropsychopharmacology*, 28, 599–609.

Uhlhaas, P. J., & Singer, W. (2010). Abnormal neural oscillations and synchrony in schizophrenia. *Nat Rev Neurosci*, 11, 100–113.

Vermeulen, J., De Preter, K., Lefever, S., Nuytens, J., De Vloed, F., Derveaux, S., et al. (2011). Measurable impact of RNA quality on gene expression results from quantitative PCR. *Nucleic Acids Res*, 39, e63.

Vivien, D., & Ali, C. (2006). Transforming growth factor-beta signalling in brain disorders. *Cytokine Growth Factor Rev*, 17, 121–128.

**Supplementary material available online**

Supplementary Methods 1 and 2, Tables 1–5 and Figures 1–3.